Arun J. Sanyal (@arunjsanyalvcu) 's Twitter Profile
Arun J. Sanyal

@arunjsanyalvcu

The views expressed here do not necessarily reflect those of VCU or its medical school or the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health.

ID: 1689283345539031041

linkhttps://liverinstitute.medschool.vcu.edu calendar_today09-08-2023 14:32:12

253 Tweet

532 Followers

87 Following

NEJM (@nejm) 's Twitter Profile Photo

For patients with metabolic dysfunction–associated steatohepatitis and liver fibrosis, survodutide, a dual agonist of the glucagon and GLP-1 receptors, may confer clinical advantages. Research findings are summarized in a new Quick Take video. nej.md/3SmZ2im

For patients with metabolic dysfunction–associated steatohepatitis and liver fibrosis, survodutide, a dual agonist of the glucagon and GLP-1 receptors, may confer clinical advantages. Research findings are summarized in a new Quick Take video. nej.md/3SmZ2im
NEJM (@nejm) 's Twitter Profile Photo

In a new trial, researchers evaluated the efficacy and safety of multiple subcutaneous doses of survodutide, a dual agonist of the glucagon receptor and GLP-1 receptor, in participants with MASH and liver fibrosis. Full trial results: nej.md/4bBXQPF

In a new trial, researchers evaluated the efficacy and safety of multiple subcutaneous doses of survodutide, a dual agonist of the glucagon receptor and GLP-1 receptor, in participants with MASH and liver fibrosis. Full trial results: nej.md/4bBXQPF
Arun J. Sanyal (@arunjsanyalvcu) 's Twitter Profile Photo

As many of you know, nurturing the next-gen of HEP is dear to my heart. I want to congratulate our own Madison Nguyen, a rising third year resident at #VCU SOM, for her selection as an @AASLD Emerging #Liver Scholar for 2024. bit.ly/3SuFxED #livertwitter

As many of you know, nurturing the next-gen of HEP is dear to my heart. I want to congratulate our own Madison Nguyen, a rising third year resident at #VCU SOM, for her selection as an @AASLD Emerging #Liver Scholar for 2024. bit.ly/3SuFxED #livertwitter
Arun J. Sanyal (@arunjsanyalvcu) 's Twitter Profile Photo

Looking forward to the event and the opportunity to connect with policymakers about liver disease and its tremendous global impact.

VCU Stravitz-Sanyal Institute for Liver Disease (@vcu_liver) 's Twitter Profile Photo

"With the urgent unmet need of patients with +MASH, we hope that AIM-MASH can aid pathologists in the clinical trial setting.” --the paper's co-authors include director Arun J. Sanyal.

Fatty Liver Foundation (@liversaver) 's Twitter Profile Photo

Missed our #webinar this week on #MASH and its effects on people living with #HIV? Watch the recording of the webinar using the following link! ➡️ bit.ly/3yGGBi1 #livertwitter #MASH #HIV

Jeffrey V. Lazarus (@jvlazarus) 's Twitter Profile Photo

We are busy preparing for the first United Nations General Assembly MASH side-event, 23 Sept 2024 - in NYC. We need a whole-of-society effort to end this public health threat. For ex food inequity + insecurity are MASLD and MASH risk factors: nature.com/articles/s4157… #LiverTwitter

We are busy preparing for the first United Nations General Assembly MASH side-event, 23 Sept 2024 - in NYC. We need a whole-of-society effort to end this public health threat.
For ex food inequity + insecurity are MASLD and MASH risk factors:
nature.com/articles/s4157… #LiverTwitter
Paris MASH Meeting (@mashparis) 's Twitter Profile Photo

Want to be part of the latest clinical breakthroughs in MASLD? Paris MASH 2024 is where it happens. Secure your seat today and don’t miss the debate on Met-ALD classification! #MASH2024 #ClinicalInnovation #RegisterNow paris-mash.org

Want to be part of the latest clinical breakthroughs in MASLD? Paris MASH 2024 is where it happens. Secure your seat today and don’t miss the debate on Met-ALD classification! #MASH2024 #ClinicalInnovation #RegisterNow paris-mash.org
Paris MASH Meeting (@mashparis) 's Twitter Profile Photo

Ready to shape the future of MASLD treatment? Paris MASH 2024 is your gateway to the latest in clinical trials and research strategies. Spots are filling fast—register now! #MASH2024 #ClinicalTrials #RegisterToday paris-mash.org

Ready to shape the future of MASLD treatment? Paris MASH 2024 is your gateway to the latest in clinical trials and research strategies. Spots are filling fast—register now! #MASH2024 #ClinicalTrials #RegisterToday paris-mash.org
VCU Stravitz-Sanyal Institute for Liver Disease (@vcu_liver) 's Twitter Profile Photo

ICYMI! Participate in the first ALF #Liver Life Walk here in Richmond on Sat., Oct. 12. Donate or sign up to walk with team “UnStoppable VCU Liver” at liverlifewalk.org/virginia/ #LiverLifeWalk #UnStoppableVCULiver #LiverTwitter VCU Stravitz-Sanyal Institute for Liver Disease American Liver Foundation National

ICYMI! Participate in the first ALF #Liver Life Walk here in Richmond on Sat., Oct. 12. Donate or sign up to walk with team “UnStoppable VCU Liver” at liverlifewalk.org/virginia/

#LiverLifeWalk #UnStoppableVCULiver #LiverTwitter 
<a href="/VCU_Liver/">VCU Stravitz-Sanyal Institute for Liver Disease</a>
 
<a href="/liverUSA/">American Liver Foundation National</a>
Paris MASH Meeting (@mashparis) 's Twitter Profile Photo

Just one day to go! Finalize your plans and register now to be part of the Paris MASH Meeting 2024. It’s not too late to join us! #MASH2024 #MASLD #LastChance paris-mash.org/registration

Just one day to go! Finalize your plans and register now to be part of the Paris MASH Meeting 2024. It’s not too late to join us! #MASH2024 #MASLD #LastChance paris-mash.org/registration
Arun J. Sanyal (@arunjsanyalvcu) 's Twitter Profile Photo

In The Lancet: GLP-1 receptor agonists, such as semaglutide, could curb both health & economic effects of obesity. In a Viewpoint, authors analyse GLP-1 receptor agonist coverage policies in 13 high-income countries to draw lessons for policy development: bit.ly/47gX2yz